Silo Pharma, Inc. (SILO)
| Market Cap | 2.11M -56.0% |
| Revenue (ttm) | 54,077 -25.0% |
| Net Income | -4.47M |
| EPS | -5.07 |
| Shares Out | 1.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 35,123 |
| Open | 1.260 |
| Previous Close | 1.290 |
| Day's Range | 1.250 - 1.365 |
| 52-Week Range | 1.100 - 10.425 |
| Beta | 0.91 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 20, 2026 |
About SILO
Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. In addition, the company is developing SP-26, a ... [Read more]
Financial Performance
In 2025, Silo Pharma's revenue was $72,102, a change of 0.00% compared to the previous year's $72,102. Losses were -$4.23 million, -3.76% less than in 2024.
Financial StatementsNews
Silo Pharma’s QwikAgents expands AI agent platform with Nvidia model support
Silo Pharma (SILO) announced that QwikAgents has expanded its AI agent platform with new customer choice across both AI models and agent software, including support for customer-supplied NVIDIA (NVDA)...
Silo Pharma's QwikAgents Expands AI Agent Platform with NVIDIA Model Support and New Runtime Flexibility
Addition of NVIDIA Nemotron models and Hermes runtime expands customer choice across both AI models and agent software SARASOTA, FLA., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“S...
Silo Pharma receives U.S. patent allowance for SPC-15 PTSD treatment
Silo Pharma (SILO) announced that the United States Patent and Trademark Office, USPTO, has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15, a novel…
Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio
Allowed claims cover compositions and methods for preventing or mitigating stress-induced behavioral responses SARASOTA, FLA., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or ...
Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum
SARASOTA, FLA., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), ”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug deli...
Silo Pharma receives notice of allowance from CIPO for PTSD treatment
Silo Pharma (SILO) announced that the Canadian Intellectual Property Office, or CIPO, has issued a notice of allowance for a patent application covering its lead asset, SPC-15, an intranasal 5-HT4…
Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment
Follows recent European patent grant and coverage in multiple international markets as Silo continues to strengthen licensed IP portfolio for lead therapeutic program
Silo Pharma granted European patent covering PTSD therapy
Silo Pharma (SILO) announced that the European Patent Office has granted a patent covering the preventative approach of its lead candidate SPC-15, a novel intranasal, nose-to-brain treatment targeting...
Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform
Collaboration supports development of a next-generation AWS-native platform designed to accelerate commercialization, scalability and enterprise adoption
Silo Pharma files to sell 1.91M shares of common stock for holders
16:07 EDT Silo Pharma (SILO) files to sell 1.91M shares of common stock for holders
Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program
Silo continues to add technology assets as it expands its AI business and further develops its lead PTSD therapeutic candidate
Silo Pharma subsidiary QwikAgents joins AMD AI program
Silo Pharma (SILO) announced that its wholly owned subsidiary, QwikAgents, has been accepted into the Advanced Micro Devices’ (AMD) artificial intelligence developer program. Participation in the prog...
Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform
Access to AMD Developer Cloud credits, AI development tools and technical resources to support next-generation enterprise AI agents Access to AMD Developer Cloud credits, AI development tools and tech...
Silo Pharma prices $11.7M at-the-market offering at $6.45 per share
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
$4 million upfront with up to approximately $7.7 million of potential additional gross proceeds upon the exercise in full of warrants in cash
Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program
NVIDIA developer program resources expected to support autonomous AI agent innovation and marketing NVIDIA developer program resources expected to support autonomous AI agent innovation and marketing
Silo Pharma engages Resyca to conduct a robustness study for SPC-15 delivery
Silo Pharma (SILO) announced that it has engaged its drug-device development partner Resyca to conduct a robustness study evaluating the microchip-based nasal spray system used for nose-to-brain deliv...
Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request
Study designed to evaluate performance and formulation stability of proprietary nose-to-brain delivery system
Silo Pharma reports positive stability data for stress treatment SPC-15
Silo Pharma (SILO) announced positive physical, chemical, and microbiological stability data for its investigational intranasal candidate, SPC-15, through nine months of real-time testing. The testing...
Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial
Positive data supports the continued advancement of FDA Investigational New Drug (IND)- enabling development program SARASOTA, FLA., June 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo...
Silo Pharma regains compliance with Nasdaq min bid price requirement
Silo Pharma (SILO) announced that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market informing the Company that, as of June 17, 2026, it has regained…
Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
SARASOTA, FLA., June 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery ...
Silo Pharma Inc trading halted, news pending
19:50 EDT Silo Pharma (SILO) Inc trading halted, news pending
Silo Pharma files provisional patent for ibogaine-based therapeutics
Silo Pharma (SILO) announced a strategic initiative to explore ibogaine-based therapeutics for the treatment of traumatic brain injury and associated neuropsychiatric conditions. Silo has filed a prov...
Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury
New initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation using psychedelic medicines